Twist Bioscience and Ono Pharmaceutical have signed a drug discovery and development agreement for new antibodies to treat autoimmune diseases.
Twist will use the Twist Biopharma Solutions Library of Libraries to carry out research into antibodies against Ono-identified targets.
The Library of Libraries is a collection of synthesised antibody libraries created from naturally occurring sequences.
These libraries utilise structural and developmental features to encompass a diverse range of drug targets.
Twist will obtain research fees at clinical and regulatory milestones based on success, and product sales royalties.
Twist Bioscience CEO and co-founder Emily Leproust stated: “Ono has a strong and proven track record in developing antibody candidates in areas of need, including the development of the anti-PD-1 antibody Opdivo, which has had a tremendous impact on patients and researchers.
“This collaboration, bringing together our antibody discovery expertise with Ono’s experience in drug development, has the potential to lead to future breakthrough treatment options for patients with autoimmune diseases.”
Ono will also make use of the scientific expertise of the Biopharma Solutions team and the premium project management services of Twist to assess new targets and generate comprehensive discovery campaigns.
Ono will oversee the activities related to the development, manufacturing and commercialisation of products that arise from the collaboration.
Ono Discovery and Research senior executive officer and executive director Dr Toichi Takino stated: “We believe that this new collaboration will enhance our biologics drug discovery efforts and bring innovative drugs for patients as soon as possible.”